A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality.
BACKGROUND
Evidence suggests that systemic inflammation may adversely impact HDL function. In this study we sought to evaluate the independent and incremental predictive performance of GlycA-a novel serum inflammatory biomarker that is an aggregate measure of enzymatically glycosylated acute phase proteins-and HDL subclasses on adverse events in a retrospective observational study of a secondary prevention population and to understand a priori defined potential interactions between GlycA and HDL subclasses.


METHODS
GlycA and HDL subclasses were measured using proton nuclear magnetic resonance spectroscopy in 7617 individuals in the CATHGEN (CATHeterization GENetics) cardiac catheterization biorepository.


RESULTS
GlycA was associated with presence [odds ratio (OR) 1.07 (1.02-1.13), P = 0.01] and extent [OR 1.08 (1.03, 1.12) P < 0.0005] of coronary artery disease and with all-cause mortality [hazard ratio (HR) 1.34 (1.29-1.39), P < 0.0001], cardiovascular mortality [1.37 (1.30-1.45), P < 0.0001] and noncardiovascular mortality [1.46 (1.39-1.54) P < 0.0001] in models adjusted for 10 cardiovascular risk factors. GlycA and smaller HDL subclasses had independent but opposite effects on mortality risk prediction, with smaller HDL subclasses being protective [HR 0.69 (0.66-0.72), P < 0.0001]. There was an interaction between GlycA and smaller HDL subclasses-increasing GlycA concentrations attenuated the inverse association of smaller HDL subclasses with mortality. Adding GlycA and smaller HDL subclasses into the GRACE (Global Registry of Acute Coronary Events) and Framingham Heart Study Risk Scores improved mortality risk prediction, discrimination and reclassification.


CONCLUSIONS
These findings highlight the interaction of systemic inflammation and HDL with clinical outcomes and may increase precision for clinical risk assessment in secondary prevention populations.
Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; robert.mcgarrah@dm.duke.edu.|Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Robert W
RW
McGarrah
Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC.|Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.|Duke Clinical Research Institute, Duke University, Durham, NC.
Jacob P
JP
Kelly
Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Damian M
DM
Craig
Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Carol
C
Haynes
Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC.
Ryan C
RC
Jessee
Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.|Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC.
Kim M
KM
Huffman
Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC.|Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
William E
WE
Kraus
Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC.|Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.|Duke Clinical Research Institute, Duke University, Durham, NC.
Svati H
SH
Shah
D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood* / Q000145:classification; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019906:Nuclear Magnetic Resonance, Biomolecular; D011134:Polysaccharides / Q000097:blood*; D015996:Survival Rate
D015415:Biomarkers; D008076:Cholesterol, HDL; D008074:Lipoproteins; D011134:Polysaccharides